Literature DB >> 23800697

Therapeutic vaccines for ovarian cancer.

John B Liao1, Mary L Disis.   

Abstract

While therapeutic vaccines for ovarian cancer represent only a small fraction of active clinical trials, growing interest in this area and the accumulated data supporting the use of vaccines in cancer treatment portend further expansion of trials incorporating these strategies. This review explores the rationale for the use of vaccines for the treatment of ovarian cancer. It examines vaccine platforms that have been investigated and reviews the data from these studies. We also highlight recently reported phase 2 and 3 clinical trials with clinical outcomes as endpoints. Finally, we consider directions for the next generation of vaccines in light of these findings and our emerging understanding of agents that may augment vaccine responses by targeting the immunosuppressive impact of the tumor microenvironment.
© 2013.

Entities:  

Keywords:  Immune therapies; Ovarian cancer; Vaccines

Mesh:

Substances:

Year:  2013        PMID: 23800697     DOI: 10.1016/j.ygyno.2013.06.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Active Delivery of VLPs Promotes Anti-Tumor Activity in a Mouse Ovarian Tumor Model.

Authors:  Chao Wang; Berta Esteban Fernández de Ávila; Rodolfo Mundaca-Uribe; Miguel Angel Lopez-Ramirez; Doris E Ramírez-Herrera; Sourabh Shukla; Nicole F Steinmetz; Joseph Wang
Journal:  Small       Date:  2020-04-24       Impact factor: 13.281

Review 2.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

Review 3.  Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.

Authors:  Bruna Corradetti; Simone Pisano; Robert Steven Conlan; Mauro Ferrari
Journal:  J Pharmacol Exp Ther       Date:  2019-02-08       Impact factor: 4.030

Review 4.  Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Authors:  Dmitriy Zamarin; Amir A Jazaeri
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

5.  Cowpea Mosaic Virus Promotes Anti-Tumor Activity and Immune Memory in a Mouse Ovarian Tumor Model.

Authors:  Chao Wang; Steven N Fiering; Nicole F Steinmetz
Journal:  Adv Ther (Weinh)       Date:  2019-02-25

6.  Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells.

Authors:  Dong-hui Wang; Xiao-hua Wu; Su-min Qian; Hai-Rong Yao
Journal:  Med Oncol       Date:  2015-03-17       Impact factor: 3.064

Review 7.  Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives.

Authors:  Ahmad Awada; Sarfraz Ahmad; Nathalie D McKenzie; Robert W Holloway
Journal:  Onco Targets Ther       Date:  2022-08-10       Impact factor: 4.345

Review 8.  Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies.

Authors:  Ariel Bulua Bourla; Dmitriy Zamarin
Journal:  Oncology (Williston Park)       Date:  2016-01       Impact factor: 2.990

9.  Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10.

Authors:  Douglas M Marvel; Olivera J Finn
Journal:  Front Immunol       Date:  2014-02-17       Impact factor: 7.561

Review 10.  Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Authors:  Thomas J Herzog; Bradley J Monk
Journal:  Gynecol Oncol Res Pract       Date:  2017-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.